[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urti---viral-upper-respiratory-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urti---viral-upper-respiratory-tract-infection":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100634157","potential-of-interface-care-models-to-deliver-more-appropriate-care-to-patients-with-acute-medical-illness-100634157",false,"NCT07536035","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness in Singapore and Decrease Utilisation of Acute Care Bed-days","Inclusion Criteria:\n\n* AMU inclusion criteria - admission from ED to AMU directly\n* Control group inclusion criteria - admission from ED to GW directly\n* Acute medical illnesses that includes infection-related conditions, falls-disequilibrium, and acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).\n\nExclusion Criteria:\n\n* Below 21 years old\n* Patients undergoing active chemotherapy\n* Patients with active pregnancy\n* Patients admitted less than 24 hours\n* Cerebrovascular disease requiring thrombolysis or intravascular intervention","ALL","21 Years",{"count":19,"type":20},220,"ESTIMATED","OBSERVATIONAL","Every country in the world is experiencing growth in both the size and the proportion of older persons. As a result of the changes, the profile and needs of people with medical illnesses have evolved. How care is delivered to patients has to keep pace with these changes, or patients will experience poor care at high cost and not have their needs met. A new model of care has emerged to meet these challenges: Acute Medical Unit. Despite considerable investment and popularity of this model, questions remain: (i) Who benefits most from this care model? (ii) How may these models be most effectively implemented for the best results? (iii) How effective are these models? Singapore is well-placed to answer these questions with its national healthcare system and excellent research institutions. The investigators plan to study how effective the model is by comparing patients with similar profiles exposed to both these care models compared to how hospital care is usually provided, looking for four differences: (i) how long patients stay in hospital, (ii) how often they use the emergency department (iii) quality of health (iv) cost. Additionally, the investigators seek to characterise patterns of health needs for this group of patients.",[24,25,26,27,28,29,30,31,32],"Falls Injury","Falls","Hospitalization in Acute Care","Chronic Obstructive Pulmonary Disease (COPD)","Infection","Acute Exacerbation of Asthma","Pneumonia","UTI - Urinary Tract Infection","URTI - Viral Upper Respiratory Tract Infection",[34,35,36,37,38,39,40],"Acute Medical Unit","Acute Medicine","Interface Care","Clinical effectiveness","Cost effectiveness","prospective observational","matched controlled","RECRUITING","2026-04-10",{"date":44,"type":45},"2026-04-17","ACTUAL",{"date":47,"type":45},"2024-09-30",{"date":49,"type":20},"2026-05-31",{"name":51,"class":52},"National University Hospital, Singapore","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":53},"100596147","evaluation-viral-rna-and-virus-infectivity-in-exhaled-air-before-and-after-use-of-one-dose-with-coldzyme-mouth-spray-100596147","NCT07041671","Evaluation Viral RNA and Virus Infectivity in Exhaled Air Before and After Use of One Dose With ColdZyme Mouth Spray","Evaluation of Number of Particles Containing Viral RNA and Their Virus Infectivity in Exhaled Air From Participants With Upper Respiratory Tract Infection Symptoms, Before and After Use of One Dose With ColdZyme Mouth Spray","Inclusion criteria for subject selection:\n\n* Male and female subjects above age 18 (inclusive).\n* Presence of self-reported sudden onset of at least one of the following symptoms of upper respiratory tract infection case definitions for ILI and ARI (as defined by ECDC (EU 2008, 2012, 2022): Cough, sore throat, shortness of breath, non-allergic rhinitis, fever or feverishness, malaise, headache, myalgia.\n* Otherwise of general good health, according to Investigator's judgement.\n* Willing and able to give written informed consent for participation in the investigation.\n\nExclusion criteria for subject selection.\n\n* Known allergy or hypersensitivity to the components of ColdZyme.\n* Current use of immunosuppressive therapy within the last 4 weeks prior to Visit 1 and during the investigation.\n* Diagnosed chronic respiratory disease that could potentially impact the investigation results, according to Investigator's judgement.\n* Self-reported unhealed wounds\u002Fmucosal lesions in the mouth and\u002For throat.\n* Participation in another clinical study or investigation within 30 days prior to Visit 1.\n* Active smokers\n* The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements.","18 Years",{"count":63,"type":20},200,"INTERVENTIONAL",[66],"NA","Many respiratory diseases spread through aerosols. ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The objective of this study is assessing if ColdZyme could also contribute to decreased airborne transmission by decreasing the amount of (infectious) virus that is exhaled by an infected subject.",[32],"2026-03-31",{"date":71,"type":45},"2026-04-06",{"date":73,"type":45},"2025-06-30",{"date":75,"type":20},"2028-12",{"name":77,"class":52},"Lund University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":64,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100595538","a-study-to-assess-the-effect-probiotic-supplement-on-immune-health-in-teachers-prone-to-upper-respiratory-tract-infection-100595538","NCT07033754","A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infection","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Study to Assess the Effect of ProGenr8™ (Probiotic Supplement) on Immune Health in Teachers Prone to Upper Respiratory Tract Infection (URTI)","Inclusion Criteria:\n\n1. Individuals ready to give voluntary, written informed consent to participate in thestudy.\n2. Male and female teachers aged between 18 to 50 years' (both values included) withmoderate physical activity level as per International Physical Activity Questionnaire -Short Form (IPAQ - SF).\n3. Individuals with body mass index (BMI) between 22 kg per m2 to 32.0 kg per m2\n4. High susceptibility to URTIs at least once every three months for last 1 year (at least 4to 6 episodes in a year).\n5. Individuals who have active URTI episode at screening defined as \"those having a scoreof less than equal to 5 for at least 2 symptoms out of runny nose, plugged nose,sneezing, sore throat, scratchy throat, cough or head congestion on the WURSS-21\".\n6. Commitment to adhere to routine diet and physical activity.\n7. Willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics andfiber supplements, probiotics, Echinacea, fish oil, vitamin E, etc.) at least 1 one monthprior to screening.\n8. Willing to discontinue sleep medications at least 1 month prior to screening and duringthe entire study duration.\n9. Individuals willing to complete all study-related and clinical study visits as per theprotocol.\n\nExclusion Criteria:\n\n1. Individuals with a history of rhinitis medicamentosa, anatomical nasal obstruction ordeformity, nasal reconstructive surgery, etc\n2. Individuals taking prebiotics, probiotics, synbiotics or post-biotics supplements 1 monthprior to screening.\n3. Individuals with known sensitivity to the investigational products or any excipients ofthe product.\n4. Individuals with any clinically significant abnormalities of the upper respiratory tract(such as stridor, laryngomalacia, etc.).\n5. Individuals suffering from lower respiratory tract infection (LRTI) of any origin.\n6. Any individual not willing to follow the abstinence from any home-based remedies for common cold such as steam inhalation, decoctions, and vapor rub, etc.\n7. Individuals with uncontrolled type 2 diabetes as assessed by fasting blood glucose lessthan equal to 126 mg per dL.\n8. Individuals with uncontrolled hypertension on medication and with systolic bloodpressure less than 140 and or diastolic blood pressure less than equal to 90 mmHg.\n9. Individuals who are unable to abstain from herbal or dietary supplements for URTI throughout the study period.\n10. Vaccination against influenza or swine flu within 90 days prior to screening.\n11. Those who have taken or should be taking or are taking antibiotics, antivirals, steroids,nasal decongestants, antihistamines, NSAIDs, or other medications that are expected to alleviate cold symptoms within two weeks prior to screening.\n12. History of any significant neurological and psychiatric condition which may affect theparticipation and inference of the study's end points.\n13. Participation in other clinical trials in last 90 days prior to screening\n14. Individuals with substance abuse problems (within 2 years) defined as: a) Use ofrecreational drugs (such as cocaine, methamphetamine, marijuana, etc.)\u002FNicotine, tobaccoor smoking dependence. b) High-risk drinking as defined by consumption of 4 or morealcohol containing beverages on any day or 8 or more alcohol containing beverages perweek for women and 5 or more alcohol-containing beverages on any day or 15 or morealcohol containing beverages per week for men.\n15. Individuals who have clinically significant following severe illness\n16. Females who are pregnant\u002Fplanning to be pregnant or lactating or taking any oralcontraceptives.\n17. Any condition that could, in the opinion of the investigator, preclude the individual'sability to successfully and safely complete the study or that may confound studyoutcomes","50 Years",{"count":87,"type":20},100,[66],"The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical studydesigned to assess the effects of IP on immune health in teachers prone to URTI. Approximately 179individuals aged between 18 and 50 years will be screened. Considering a screen failure of 20%,approximately 144 individuals will be randomized in a ratio of 1:1 to receive either the active orplacebo. The study will have at least 100 completed participants i.e. 50 participants in each studyarm after accounting for a dropout\u002Fwithdrawal rate of 30% at the end of the study. The interventionand follow-up duration for all the study participants will be 120 days.",[32],"NOT_YET_RECRUITING","2025-06-19",{"date":94,"type":45},"2025-06-24",{"date":96,"type":20},"2025-06-25",{"date":98,"type":20},"2026-01-20",{"name":100,"class":101},"Vedic Lifesciences Pvt. Ltd.","INDUSTRY",6]